Xcopri

Active Ingredient(s): Cenobamate
FDA Approved: * November 21, 2019
Pharm Company: * SK LIFE SCIENCE INC
Category: Anticonvulsant

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Xcopri Overview

Cenobamate, sold under the brand name Xcopri, is for the treatment of partial-onset seizures in adults.[1][2] It was approved for medical use in the United States in 2019.[1][2][3] Contents 1 Pharmacology 1.1 Pharmacodynamics 2 History 3 References 4 Further reading 5 External links Pharmacology Pharmacodynamics Cenobamate is a voltage-gated sodium channel (VGSC) blocker.[4] It is a s...

Read more Xcopri Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cenobamate

Recent Xcopri Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cenobamate
  • Tablet: 100mg, 12.5mg, 150mg, 200mg, 25mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Cenobamate or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 January 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA